Ken Griffin Gain Therapeutics, Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.21 - $5.04 $196,358 - $308,301	-61,171 Reduced 93.54%	4,223 $15,000
Q4 2023 Feb 14, 2024	BUY	$2.07 - $3.4 $40,402 - $66,361	19,518 Added 42.55%	65,394 $213,000
Q3 2023 Nov 14, 2023	BUY	$3.19 - $4.68 $30,716 - $45,063	9,629 Added 26.56%	45,876 $150,000
Q2 2023 Aug 14, 2023	BUY	$4.36 - $5.5 $81,968 - $103,400	18,800 Added 107.75%	36,247 $162,000
Q1 2023 May 15, 2023	BUY	$3.18 - $5.16 $55,481 - $90,026	17,447 New	17,447 $84,000

2.39M

10K

Ticker GANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,883,400
Market Cap $18.5M
Description
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.